ROVI informs on the notification of particulate matter having been seen in certain drug product vials of the Moderna's COVID-19 vaccine distributed in Japan

Laboratorios Farmacéuticos ROVI, S.A. has announced that an investigation is underway in relation to the reported detection of particulate matter in certain vials of Covid-19 vaccine distributed in Japan


Laboratorios Farmacéuticos ROVI, S.A. (ROVI), in compliance with the information duties set out in article 227 of the Revised Text of the Securities Market Act, as an entity participating in the manufacturing process of Moderna’s vaccine against Covid- 19, and in relation to the notification of particulate matter having been seen in certain drug product vials of the vaccine distributed in Japan, informs that ROVI is currently conducting an investigation on this event, following the standard procedure for these cases.

The detection of this particulate matter refers to certain vials of one product lot distributed exclusively in Japan. ROVI, as well as Moderna and Takeda, the company distributing the referred vaccine in Japan, are working with health authorities in order to clarify and solve, if applicable, this incident

The origin of this manufacturing incident may be in one of ROVI’s manufacturing lines. ROVI is working in order to provide with all the information and assistance that may be needed to progress with the investigation. As a precaution, this lot and two adjacent lots have been put on hold.

To date, no safety or efficacy issues have been identified in relation to the vaccine, as Moderna and Japanese authorities have reported.

ROVI will continue assisting proactively with the investigation.

No votes yet
 
Related
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
02/04/2024